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and nuclear re-organization linked to regional
epigenetic regulation in breast cancer
Sehrish Rafique1,2, Jeremy S. Thomas2, Duncan Sproul1,2* and Wendy A. Bickmore1*Abstract
Background: Epigenetic changes are being increasingly recognized as a prominent feature of cancer. This occurs
not only at individual genes, but also over larger chromosomal domains. To investigate this, we set out to identify
large chromosomal domains of epigenetic dysregulation in breast cancers.
Results: We identify large regions of coordinate down-regulation of gene expression, and other regions of
coordinate activation, in breast cancers and show that these regions are linked to tumor subtype. In particular we
show that a group of coordinately regulated regions are expressed in luminal, estrogen-receptor positive breast
tumors and cell lines. For one of these regions of coordinate gene activation, we show that regional epigenetic
regulation is accompanied by visible unfolding of large-scale chromatin structure and a repositioning of the region
within the nucleus. In MCF7 cells, we show that this depends on the presence of estrogen.
Conclusions: Our data suggest that the liganded estrogen receptor is linked to long-range changes in higher-order
chromatin organization and epigenetic dysregulation in cancer. This may suggest that as well as drugs targeting
histone modifications, it will be valuable to investigate the inhibition of protein complexes involved in chromatin
folding in cancer cells.Background
While genetic aberrations altering gene expression and
genomic stability are a hallmark of cancer, epigenetic
changes are also frequently observed and have the po-
tential to be crucial influences on carcinogenesis [1].
Epigenetic alterations have been mostly explored at the
single gene level but there are increasing reports of con-
tiguous genes being coordinately repressed in association
with tumor progression — a phenomena known as long-
range epigenetic silencing (LRES) [2, 3]. Both focal and
regional epigenetic alterations are likely to contribute to
the heterogeneity of cancer.
The tendency of genes that are clustered in the gen-
ome to be co-expressed has long been noted in many
eukaryotic genomes [4] and has been suggested to be in-
fluenced by the chromatin and nuclear environments* Correspondence: Duncan.Sproul@igmm.ed.ac.uk; Wendy.Bickmore@igmm.
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article, unless otherwise stated.across a chromosomal domain [5]. Indeed, coordinate
gene regulation has been linked to lamin-associated do-
mains (LADs), regional chromatin compaction [6] and
to topologically associated domains (TADs) [7]. How-
ever, for the most part the mechanisms underlying the
coordination of expression from clustered genes remain
unclear.
Coordinately dysregulated clusters of genes have been
reported in association with chromosomal abnormalities
[8]; however, the best described and understood in-
stances of long-range gene dysregulation come from
cancer. In these instances, LRES has been most com-
monly identified by detecting DNA methylation at the
promoters of clustered genes [9–14]. Some of these
studies have been extended to show that decreased gene
expression in these regions is accompanied by the loss
of histone modifications associated with gene activity
(e.g., H3K4me3) [9, 15] and the gain of repressive histone
marks — H3K9 methylation, H3K27me3 and histone
hypoacetylation [10, 15, 16]. Gene repression associatedle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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volve the acquisition of DNA methylation [17].
More recently, in prostate cancer long-range epigen-
etic activation (LREA) of genes has been reported, asso-
ciated with a loss of H3K27me3 and a gain of H3K9ac
[18]. The mechanism of activation is not clear but it was
suggested that it might involve DNA methylation of
promoter-associated CpG islands and transcription from
alternative promoters.
In bladder carcinoma, expression data were used to
uncover LRES regions by determining the correlation of
each gene’s expression profile with that of its neighbors
[19]. Comparative genome hybridization (CGH) data
were used to exclude regions where coordinately re-
duced expression was due to copy number aberrations.
LRES has been identified in a wide-range of epithelial
cancers (bladder, colorectal, prostate, gastric). Further-
more, the LRES phenotype can be specific to subsets of
bladder cancer and correlates with tumor stage and ag-
gressiveness [17]. In some breast tumors, epigenetic si-
lencing of HOXA and protocadherin gene clusters was
reported [9, 11]. There was no explicit investigation of
tumor subtype, although the two breast cancer cell lines
investigated (MDAMB231 and Bt 549) happen to be of
the basal-B subtype [20].
By integrating analysis of coordinate gene expression,
DNA methylation and data on estrogen receptor alpha
(ERα) binding sites in the MCF7 breast cancer cell line,
11 regions of LRES were reported in association with es-
trogen signaling [21]. For one region (16p11.2), coordin-
ate repression was estrogen-inducible in normal breast
epithelial cells and was associated with the formation of
3C (chromosome conformation capture) associations
that were interpreted as a large looped chromatin struc-
ture bringing together the promoters of the 14 silenced
genes [21].
To determine whether higher-order chromatin organization
is more generally linked to the coordinate dysregulation
of genomic regions in breast cancer and whether this is
associated with tumor subtype, we have identified re-
gions of regional epigenetic regulation (RER) that are
independent of copy number alterations in breast tumors
and breast cancer cell lines. As well as regions of LRES,
we found regions of LREA in tumors relative to normal
breast tissue. We demonstrate that regional gene expres-
sion differences within one LREA region — present in
both breast tumors and cell lines — are associated
with alterations in chromatin compaction and nuclear
organization. Chromatin at this region is visibly less
compact in ER-positive (ER+) breast cancer cells that
have the RER phenotype, compared with the ER-negative
(ER−) tumor subtypes and to normal breast epithelium. In
MCF7 cells, we show that at this locus, estrogen is respon-
sible for inducing chromatin decompaction and a morecentral position in the nucleus. This study highlights the
importance of studying regulation beyond the level of single
genes and suggests that as well as alterations to DNA
methylation and histone modifications, aberrant chro-
matin organization may contribute to genome dysregu-
lation in cancer.
Results
Regions of copy number-independent transcriptional
correlation in breast tumors
To identify chromosomal regions containing genes that
are coordinately expressed independent of genomic
changes in breast cancer, we implemented an approach
based on that used to find LRES regions in bladder cancer
[19]. We applied this to the analysis of transcription
(expression microarray) and copy number (array CGH)
from 356 breast tumors [22]. To ensure apparent RER
regions were not caused by copy number variation, we
excluded from further analysis genes for which a copy
number aberration was detected in that sample. A tran-
scription correlation score (TCS) was calculated for
each gene to quantify how well its expression correlated
with that of its neighbors. This score was the sum of
the Spearman rank correlations for a given gene’s ex-
pression with that of each of its ten nearest neighbors.
TCS maps generated from this tumor set revealed
peaks corresponding to potential RER regions (Fig. 1a,
arrows; Figure S1 in Additional file 1).
We identified 382 genes with significantly outlying
high TCSs (p < 0.05, threshold TCS 5.08, false discovery
rate (FDR) 6.6 % by permutation). The expression patterns
of genes with significant TCSs were significantly corre-
lated with that of their individual neighboring genes
(mean 15.66, range 10-20, Spearmans rho, p < 0.05).
Furthermore, they also possessed high TCSs in a second
independent set of breast tumors [23] (Fig. 1b), demon-
strating that our result was not particular to the dataset
analyzed. We merged adjacent significant TCS windows
to delineate 45 RER regions that included at least two
genes with significant scores. These regions ranged in
size from 0.12 Mb to 43 Mb (median 1.86 Mb) (Table
S1 in Additional file 1).
Consistent with a coordinately regulated gene expression
signature, the identified RER regions included one
(6p22.1-p22.3) that contains the histone gene cluster
whose expression is coordinately regulated in early S
phase [24]. This region also includes GMNN, which en-
codes the replication licensing inhibitor geminin and
whose expression also peaks in S phase [25].
Overall, RER in breast cancer occurs in regions of the
genome that are significantly more gene dense than
expected by chance (Figure S2a in Additional file 1).
Analysis of Gene Ontology associated with the signifi-
cant TCS genes highlighted terms associated with
Fig. 1 Identifying RER in breast tumors and cancer cell lines. a, c Transcription correlation score (TCS) maps for chromosomes 3 and 16 using
data from breast tumors [22] (a) and breast cancer cell lines [20] (c). The horizontal dotted line indicates the significance threshold. Arrows indicate
regions containing genes with significant TCSs. b Boxplots showing the distribution of TCSs generated for all genes and for RER genes using two
independent breast tumor datasets [22, 23]. d Ideograms showing the location of the 45 RER regions identified in breast tumors (red) and the 71
RER regions identified in breast cancer cell lines (blue)
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EGFR/ERRB pathway, known to be very important in
the biology of breast cancer (Figure S2b in Additional
file 1). Five subunits of the mediator complex, which is
involved in transcriptional regulation, especially by nu-
clear receptors [26], are encoded by genes with significant
TCSs in four RER regions. Seven genes encoding mito-
chondrial ribosomal proteins have significant TCSs in
six RER regions (Table S1 in Additional file 1).Expression of genes involved in mitochondrial biogenesis
and function, and especially those encoding mitochondrial
ribosomal proteins, is particularly elevated in epithelial
cancer cells [27].
RER regions show differential expression in breast tumor
subtypes
We compared gene expression levels in the RER regions
in breast tumors with those in bulk normal breast tissues,
Rafique et al. Genome Biology  (2015) 16:145 Page 4 of 19using datasets from [28, 29] that also include expression
data derived from breast organoid preparations which are
enriched in the epithelial cells known to give rise to tu-
mors. There were examples where RER region expression
was significantly (p < 0.05) up-regulated in ER− and
down-regulated in ER+ tumors (2p24.2-p25.1; Fig. 2a), or
vice versa (18q12.3-q21.32), relative to normal tissue or
organoids. An RER region at 12q15-q21.33 (Fig. 2b) was
down-regulated relative to normal only in ER− tumors
and one at 14q23.3-q32.11 had a similar pattern only in
ER+ tumors. Elevated expression in ER− tumors only
(i.e., no significant change in ER+ tumors) relative to
normal organoid was seen in two instances (16q12.2-
q24.1 and 20q13.2-q13.33). Expression was up-regulated
in ER+ tumors only, relative to normal, in a total of 12
RER regions, (e.g., RER region 16p11.2; Fig. 2c). Finally,Bulk Normal Normal
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between tumor and normal samples taken togetherexpression was up-regulated in both tumor types relative
to normal in 13 RER regions.
To better understand the patterns of coordinate gene
expression in relation to tumor biology, we examined
heat maps of gene expression data for significant TCS
genes in RER domains. For many of these regions,
unsupervised hierarchical clustering separated breast
tumors by the intrinsic subtypes previously defined by
gene expression [30] (e.g., luminal and basal-like) and
revealed cases where there is a tumor subtype-specific
gene signature (activation or repression) within RER
regions. For example, an RER region at 3p14-p21.31
(Fig. 3a) has elevated expression in luminal (ER+) relative
to basal tumors (ER−), whereas one at 16q12.2-q24.1
(Fig. 3b) is repressed in luminal ER+ relative to basal
type tumors.−
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Fig. 3 Properties of RER regions and tumor subtypes. a Unsupervised hierarchical cluster analysis of breast tumor samples for RER regions at
3p14-p21.31 (left) and 16q12.2-q24.1 (right). Heat maps of gene expression z scores with hierarchical clustering of samples (red high expression,
green low expression). Genes are ordered by their position in the genome. Subtype information [22] for each tumor sample is identified by the
color-coded matrix: luminal A (blue), luminal B (turquoise), ERBB2 (purple), basal (red), normal-like (green). Only genes in the regions with significant
TCSs are shown. b As in (a) but for mean expression (mean z score of genes with significant TCSs) for all RER regions in each breast tumor sample,
showing clustering of RER regions into three groups. Both the RER regions and samples were subject to hierarchical clustering. c Box plots showing
mean expression (mean z score of genes with significant TCSs) of RER regions from clusters 1, 2 and 3 in breast tumors of different subtypes; luminal A
(LumA, blue), luminal B (LumB, turquoise), ERBB2 (purple), basal-like (red). **p < 0.01, ***p < 0.001, Wilcoxon test)
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breast tumors are independent of each other or whether
they might be co-expressed in the same tumor, we ana-
lyzed the mean expression patterns of the 45 RER regions
and found that they fall into three co-expressed clusters(Fig. 3b). The highest mean expression of cluster 1 RER
regions is detected in luminal B subtype tumors whereas
cluster 2 RER regions are preferentially expressed in
luminal A tumors, and cluster 3 RER regions in basal-like
tumors (Fig. 3c).
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To gain more mechanistic insight into the factors affect-
ing the formation of RER regions in a tractable experi-
mental system, we also generated TCS maps for 48
breast cancer cell lines [20]. This revealed 557 genes
grouped into 71 regions of copy number-independent
transcriptional correlation, 0.1–15.8 Mb (median 0.9. Mb)
in size (Fig. 1c; Figure S3 and Table S2 in Additional file 1).
The smaller average RER region size in cell lines com-
pared with tumors likely reflects the better genome
coverage of the expression array platforms used for the
former. Apart from this difference, transcription correl-
ation maps from breast tumors and cell lines were quite
similar (Fig. 1c).
In total we identified 26 copy number-independent re-
gions of coordinate expression (0.23–13.4 Mb in size
(median 1.40 Mb)) that are in common between breast
tumors and breast cancer cell lines (Table 1). Gene expres-
sion was up-regulated relative to normal breast in nine of
these RER regions and it was down-regulated in a further
eight regions. The remaining regions showed no signifi-
cant change in expression between cancer and normal
cells, i.e., at these genomic regions coordinate gene regula-
tion is either typical of both the normal and the cancerous
state or is balanced out overall by changes in different
directions in different tumor subtypes (e.g., Fig. 2a).
For cell line RER regions equivalent to those from
tumor RER regions of cluster 1, mean expression levels
were higher in ER+ than in ER− cell lines (Fig. 4a, b).
The expression of cluster 2 and 3 RER regions was not
so well modeled in the cell lines (Fig. 4c, d). This might
reflect the fact that the majority of breast cancer cell
lines were established from advanced cancers and thus
luminal cell lines would be expected to be equivalent to
luminal B tumors (which express cluster 1 RER regions)
rather than less aggressive luminal A tumors (which ex-
press cluster 2 RER regions). Similarly, many ER− breast
cancer cell lines are known to reflect the claudin-low,
mesenchymal subtype of breast tumor, which is very rare
in vivo [20].
Chromatin and nuclear reorganization of RER domains
One of the cluster 1 RER regions common to both the
tumor and cell line datasets is on chromosome 16p11.2
and encompasses a region previously reported as regu-
lated by LRES in estrogen-responsive breast cancer cells
[21]. Our analysis of expression for all genes in this RER
region (not just those with a significant TCS) revealed a
differential expression pattern between luminal, ER+ and
basal, ER− breast cancer subtypes, with increased gene
expression in luminal tumors (Fig. 2c). This is replicated
in breast cancer cell lines — mean expression levels
within this RER region are higher in ER+ breast cancer
cell lines than in ER− ones (Fig. 4a, b).To determine whether 16p11.2 is one contiguous
block of RER, or several different subregions, we analyzed
TCSs generated by varying the number of neighboring
genes (n) used in the sliding window analysis (from 10 —
the value used for the original analysis – down to 1). As n
decreased to 8 and below, genes with remaining high
TCSs were resolved into distinct two RER subregions (2
and 3) that are located more proximal on 16p11.2 than
the LRES region defined by Hsu et al. [21] (subregion 1 in
Fig. 5a).
We have previously shown that fluorescence in situ
hybridization (FISH) can detect long-range chromatin
decompaction that occurs as a result of differentiation,
perturbation of epigenetic mechanisms or signaling
pathways, or genetic disorders [31–34]. To determine
whether the changes in gene expression seen in the
16p11.2 RER region also correspond to altered large-
scale chromatin compaction, we performed FISH using
probes located at the boundaries of the two ~400 kb
subregions defined in Fig. 5a on nuclei of the luminal ER
+ MCF7 and basal-type ER− MDAMB231 breast cancer
cell lines [20] (subregions 2 and 3). These were com-
pared to two adjacent subregions that were less enriched
in genes with significant TCSs (subregions 1 and 4).
Analysis of the normalized inter-probe distance (d2/r2)
[32] revealed that only subregion 2 showed a significant
(p = 0.03, Wilcoxon rank-sum test) difference in chro-
matin compaction between MCF7 and MDAMB231,
with the region being de-compact in MCF7 cells (Fig. 5b;
Table S3 in Additional file 1).
Unsupervised hierarchical clustering of expression
data from 48 breast cancer cell lines for genes in sub-
region 2 [20] segregated luminal ER+ and basal ER− cell
line subtypes (Fig. 5c). The LY2 derivative of MCF7,
which though ER+ has estrogen-independent growth
[35], shows elevated gene expression and chromatin
decompaction within subregion 2, like parental MCF7s
(Fig. 5d; Table S3 in Additional file 1). Conversely, a sec-
ond ER− breast cancer cell line, MDAMB468, showed
reduced gene expression and a compact chromatin
structure, like MDAMB231. A less compact chromatin
structure in MCF7 and LY2 cells was not seen at nega-
tive control loci that are not within an RER region
(Figure S4 in Additional file 1).
To determine the chromatin compaction status at sub-
region 2 in a normal breast cell line, FISH was also car-
ried out on the non-transformed immortalized human
mammary epithelial cell line HMLE [36]. The chroma-
tin state of this region in HMLE was more compact
than in MCF7 and LY2 cells, but not significantly dif-
ferent to that in the ER− cell lines MDAMB231 and
MDAMB468 (Fig. 6a). A second independent ER+
breast cancer cell line, MDAMB361, showed a trend to
being more de-compact than HMLE but this difference
Table 1 Cytogenetic band(s) where RER regions common to breast tumors and breast cancer cell lines are located
Cytogenetic
location
Size (Mb) Number of
significant TCSs
(tumor/cell line)
Number of other
significantly correlated
genes (tumor/cell line)
Genes in RER regions
with significant
TCSs
Gene expression
(tumor versus
normal)
6p22.2 0.89 3/34 14/28 C6orf62, GMNN, HIST1H4C/
Histone gene cluster,
ZSCAN16, GPX5, OR2W1,
OR2J3, OR2N1P, OR12D2,
OR10C1, MOG
Up
6q23.2-q23.3 3.43 12/3 26/10 TAAR5, TAAR3, VNN3, IFNGR1,
HEBP2, ABRACL, HECA, VTA1,
PEX3, FUCA2, LTV1, SHPRH, PPIL4,
RMND1, C6orf211
Down
6q25.1-q25.3 6.71 12/3 26/7 RP23-468K3.1, RP3-527B10.1, OPRM1 Down
8p11.21-q11.23 13.41 6/6 17/8 TM2D2, GOLGA7, KAT6A, AP3M2,
IKBKB, POLB, VDAC3, SLC20A2,
SMIM19, MCM4, MRPL15
Down
8q21.13-q21.3 10.54 32/6 33/11 NBN, OTUD6B, RAD54B,
KIAA1429, ESRP1, INTS8,
PLEKHF2, MTERFD1, PTDSS1,
MTDH, HRSP12, AP003355.2,
VPS13B, ANKRD46, UBR5, AZIN1,
ATP6V1C1, SLC25A32, TTC35,
TAF2, MRPL13, DERL1, ATAD2,
WDYHV1, TRMT12,
RNF139/KCNB2, STAU2,
FAM164A, STMN2, FAM82B, MMP16
No change
8q22.1-q23.1 11.99 32/11 33/3 NBN, OTUD6B, RAD54B,
KIAA1429, ESRP1, INTS8,
PLEKHF2, MTERFD1, PTDSS1,
MTDH, RPL30, HRSP12,
AP003355.2, NIPAL2, VPS13B,
COX6C, SPAG1, RNF19A,
ANKRD46, UBR5, AZIN1,
ATP6V1C1, FZD6, SLC25A32,
EMC2, TAF2, MRPL13, DERL1,
ATAD2, WDYHV1, TRMT12, RNF139
No change
9p13.3 1.13 2/6 20/11 NOL6, SIGMAR1, KIAA1045,
DNAJB5, RUSC2, CD72, SIT1, CA9
No change
10p13-p12.31 6.71 5/3 22/10 UPF2, CDC123, HSPA14,
RPP38, NMT2, RSU1, STAM
Down
10q26.11-q26.13 6.34 3/5 21/10 BAG3, C10orf119, SEC23IP,
BRWD2, PLEKHA1, IKZF5
No change
11q12.3-q13.1 0.75 5/2 27/9 C11orf48, WDR74, COX8A,
OTUB1, MACROD1, NUDT22,
RPS6KA4
Up
11q13.2 0.36 6/2 18/9 KAT5, FIBP, CCDC85B, SART1,
SF3B2, YIF1A , SPTBN2, C11orf80
Up
12q21.31-q21.33 10.39 2/4 17/12 RAB21, PPP1R12A , NTS,
MGAT4C, DCN, EEA1
Down
16p13.3 2.16 23/23 33/22 AXIN1, TMEM8A, NME4,
RAB11FIP3, PIGQ, RAB40C,
LA16c-398G5.2, WDR90, RHOT2,
WDR24, METRN, FAM173A,
CCDC78, NARFL, IFT140, NME3,
MRPS34, HAGH, NDUFB10,
GFER, NTHL1, TRAF7, MLST8,
E4F1, GNG13, LMF1, CACNA1H,
TPSG1, TPSD1, UBE2I,
BAIAP3, PGP
Up
16p13.3 1.45 4/5 16/12 OR1F1, OR2C1, NAA60, ADCY9,
TFAP4, DNAJA3, ANKS3, ROGDI,
UBN1
Up
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Table 1 Cytogenetic band(s) where RER regions common to breast tumors and breast cancer cell lines are located (Continued)
16p12.3 0.38 3/2 13/6 KNOP1, GP2, EARS2,
NDUFAB1, PALB2
No change
16p11.2 1.36 6/25 22/13 SEZ6L2, TAOK2, HIRIP3, DOC2A,
ALDOA, PPP4C, TBX6, MAPK3,
CD2BP2, TBC1D10B, ZNF48,
ZNF771, ZNF768, ZNF747,
ZNF764, ZNF688, ZNF785,
PRR14, FBRS, SRCAP, PHKG2,
RNF40, ZNF629, BCL7C, CTF1,
SETD1A, VKORC1
Up
16q22.1-q22.2 4.9 22/11 71/17 CDH16, NOL3, E2F4, ATP6V0D1,
THAP11, PSKH1, DDX28, DUS2L,
PRMT7, COG4, VAC14
Down
17p11.2 1.69 17/3 26/6 TOM1L2, LRRC48, LLGL1 Down
17q11.2 0.53 17/4 26/6 UNC119, KIAA0100, SDF2, SUPT6H Up
17q21.2 0.28 17/6 13/9 KRTAP1-3, KRTAP1-1, KRTAP2-4,
KRTAP4-9, KRT34, KRT31
No change
17q25.1 0.9 24/4 20/6 KCTD2, GGA3, MRPS7, GRB2 Up
17q25.3 0.58 13/4 18/13 STRA13, RFNG, CSNK1D, SECTM1 Up
22q11.23-q12.1 5.93 5/13 15/20 TRMT2A, P2RX6, TOP3B, PPIL2,
IGLV1-40, ZNF280B, ZNF280A,
ZDHHC8P, VPREB3, MMP11,
UPB1, SEZ6L, CRYBB1
Down
22q12.2-q12.3 1.01 3/2 15/11 INPP5J, PIK3IP1 No change
22q12.3 0.24 3/4 15/12 TMPRSS6, SSTR3, MFNG, GCAT No change
22q13.1-q13.2 1.37 2/6 16/10 CBX6, APOBEC3A, PDGFB, MGAT3,
CACNA1I, SGSM3
No change
The RER region size (measured as the first to last significant TCS in the region), the number of genes with significant TCSs in the tumor or cell line data, the
number of other genes in the region which have significantly correlated expression with the TCS genes (again for tumors and cell lines), and the list of those
genes with significant TCSs. The gene expression of the region in tumors compared with normal samples is also indicated
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correlates with the expression level of genes in sub-
region 2 in MDAMB361, which was lower than in
MCF7s and LY2 (Fig. 5c). We also note that unlike
MCF7s and LY2 cells, MDAMB361 cells are HER2+
due to copy number amplification of the ERBB2 onco-
gene [20]. Our analysis of RER gene expression demon-
strates that the breast tumors of the ERBB2 subtype
have lower expression levels of cluster 1 RER regions
(Fig. 3b). This suggests that the expression of ERBB2
oncogene lessens RER region expression and chromatin
decompaction phenotype of cluster 1 RER regions, such
as the 16p11.2 region.
To examine chromatin structure at subregion 2
in vivo, 3D FISH was also performed on tissue sections
from an ER+ breast tumor, from an ER− tumor and
from normal breast tissue. The chromatin at this region
of 16p11.2 was most compact in normal tissue, though
this was not significantly different from that in the
ER− tumor. Chromatin at this region was, however,
significantly less compact in the ER+ tumor compared
with either the ER− tumor or normal tissue (Fig. 6b, c),
confirming that chromatin de-compaction of subregion 2
in ER+ breast cancer is not an artifact of cell culture.Estrogen mediates chromatin de-compaction and nuclear
re-organization
The association between ER status and RER within sub-
region 2 suggested that estrogen might be responsible
for the observed differences in chromatin compaction.
As well as inducing local changes in chromatin modifi-
cation, ER has been reported to be capable of inducing
large-scale visible chromatin de-condensation on an arti-
ficial reporter array [37]. Examination of chromatin im-
munoprecipitation (ChIP)-sequencing data from MCF7
cells [38] revealed seven ER-bound sites within the 400
kb subregion 2 of the 16p11.2 RER region (Fig. 7a). A
permutation analysis of 10,000 randomly placed genomic
windows of equal size to subregion 2 (~414 kb; using
BEDtools v.2.17.0) showed that subregion 2 is among
the top 6.2 % of regions in the human genome in terms
of enrichment for ER binding sites.
To test whether the de-compact chromatin state of
subregion 2 in MCF7 cells depends on estrogen, MCF7
and the ER− breast tumor cell line MDAMB231 were
cultured in phenol-free media with fetal calf serum
(FCS) that had been stripped of all endogenous hormones
(−E2 in Fig. 7). This resulted in a significant (p = 0.002)
compaction of chromatin at subregion 2 in MCF7 cells
Fig. 4 Properties of RER regions in breast cancer cell lines. Analysis of mean expression (mean z score of genes with significant TCSs) levels in
breast cancer cell lines for cluster 1 RER regions (a) and RER regions of clusters 2 and 3 (c). RER regions were subject to hierarchical clustering and
cell lines were ordered by their overall level of expression of each RER cluster. Box plots showing mean expression (mean z score of genes with
significant TCSs) of RER regions from cluster 1 (b) and clusters 2 and 3 (d) in ER+ (gray) and ER− (white) breast cancer cell lines (*p < 0.05, ***p < 0.001)
Rafique et al. Genome Biology  (2015) 16:145 Page 9 of 19(Fig. 7b), but not in MDAMB231 (p = 0.41) (Fig. 7c). The
cells were then treated with 100 nM 17β-estradiol (estro-
gen, E2) for 24 hours (+E2 in Fig. 7). These conditions
activate high-level expression of estrogen-regulated genes
in MCF7 cells [39]. E2 treatment resulted in chromatin
de-compaction of subregion 2 in MCF7 cells relative to
the –E2 conditions (p = 0.003) and a return to a chroma-
tin compaction state similar to that seen in MCF7 cells
grown in normal serum (p = 0.52). Addition of E2 to
MDAMB231 cells had no effect on chromatin compaction
in this region (p = 0.32). Chromatin de-compaction inMCF7 cells upon the addition of E2 was not seen at a
control locus outside of the 16p11.2 locus 2 RER region
(Figure S5 in Additional file 1).
As well as changes in chromatin condensation, the ra-
dial position of some genes in the nucleus has been
linked to their activity [33, 40]. We therefore quantified
the radial nuclear position of subregion 2 of the 16p11.2
RER region across five shells of equal area eroded from
the periphery (shell 1) through to the center (shell 5) of
the nucleus in MCF7 cells. As expected, given the known
preferred position of gene-rich human chromosome 16
Fig. 5 Refinement and analysis of the 16p11.2 RER region in breast cancer cell lines. a Black bars indicate genes along 16p11.2, oriented from
centromere (top) to telomere (bottom), which have significant TCSs at varying window (2n + 1) size with n from 1 to 10. Gene expression data
are from tumor cell lines [20]. Gene names are listed to the right, as are the position of fluorescence in situ hybridization (FISH) probes that were
used to examine the four RER subregions. b Box plots show the distribution of normalized FISH interprobe distances (d2/r2) [31, 32] measured
across the four subregions of the 16p11.2 RER region in MCF7 and MDAMB231 breast cancer cell lines. n = 45–60 nuclei. The significance of
differences between datasets was assessed by Wilcox test (Table S3 in Additional file 1). c Unsupervised cluster analysis of gene expression z
scores for subregion 2 in 48 breast cancer cell lines (red ER−, blue ER+) [20]. Cell line names are indicated along the bottom of the heat map.
Red/green z scores equate to increased/decreased gene expression, respectively. Genes are ordered by their position on the chromosome and listed to
the right. The yellow boxes indicate cell lines examined by FISH. d Example FISH images using probe pairs (red and green) that delineate subregion 2
(as in (a)) in ER+ cell lines MCF7 and LY2 (upper panels), and ER− cell lines MDAMB231 and MDAMB468 (lower panels). DNA is stained with DAPI (blue).
Scale bar = 5 μm. The boxplots to the right show the distribution of normalized FISH interprobe distances (d2/r2) across subregion 2 in the four cell
lines. n = 45–60 nuclei. The significance of differences between datasets was assessed by Wilcox test (Table S3 in Additional file 1)
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from subregion 2 were predominantly found in the nuclear
center (Fig. 7d). Hormone deprivation led to a significant
re-localization of the region away from the nuclear center,
and central nuclear localization was restored by the re-
addition of estrogen. In contrast, in the ER− cell line
MDAMB231 the removal of hormone by growth in
stripped media did not affect the localization of the
16p11.2 RER region and the re-addition of estrogen re-
sulted in the locus adopting a less central position in
the nucleus (Fig. 7e).
These data are consistent with the hypothesis that the
de-compact higher-order chromatin state and the main-
tenance of a central nuclear localization of subregion 2
in ER+ breast cancer cells with an RER phenotype is me-
diated by the action of estrogen itself.Discussion
Regional epigenetic regulation in breast cancer
Dysregulation of gene expression is a common event in
cancer, and a number of long-range events have been
documented in various solid tumors. These studies have
generally uncovered large chromosomal domains associ-
ated with gene repression and are accompanied by a
cocktail of cancer-associated epigenetic changes in DNA
methylation and histone modifications associated with
repression [2, 3, 9–17]. Less frequently documented has
been the coordinate up-regulation of genes in chromo-
somal domains in cancer [18].
Here we identify regional epigenetic regulation that is
present in breast tumors and breast cancer cell lines. We
found regions of copy-number independent coordinate
down-regulation of gene expression (LRES) relative to
Fig. 6 Chromatin compaction at subregion 2 of the 16p11.2 RER region in breast cancer cell lines, in normal breast tissue and in primary breast
tumors. a Box plots comparing the distribution of normalized FISH interprobe distances (d2/r2) measured across subregion 2 of the 16p11.2 RER
region in a normal breast cell line (HMLE) and in ER+ (MCF7, LY2, MDAMB361) and ER− (MDAMB231 and MDAMB468) breast cancer cell lines.
n = 45–60 cells. The significance of differences between datasets was assessed by Wilcox test (Table S3 in Additional file 1). b Box plots
showing the distribution of normalized FISH interprobe distances (d2/r2) measured across subregion 2 of the 16p11.2 RER region in normal
breast tissue and in ER+ and ER− tumor tissues. n = 250–300 alleles. Distances in the ER+ tumor were significantly greater than in normal
tissue (p < 0.0001) or in the ER− tumor (p = 0.004). Differences between normal and ER− tumor tissue were not significant (p = 0.24). c Example FISH
images using probe pairs (red and green) that delineate subregion 2 in normal breast tissue and in ER+ and ER− tumor tissue. DNA is stained with
DAPI (blue). Scale bar = 5 μm
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also regions of coordinate up-regulation (LREA). Twenty-
six RER regions were found to be in common between tu-
mors and cancer cell lines. In addition, the RER regions
we identify fall into three groups characterized by being
expressed primarily in different breast cancer subtypes.
Genes in pathways previously implicated in tumor
biology are present in RER regions, so understanding themechanisms that lead to RER formation is important. In
bladder cancers, a multiple regional epigenetic silencing
phenotype was found to occur in a subset of aggressive
tumors of the carcinoma in situ pathway but not in tu-
mors driven by mutations in FGFR3 [17]. Here, we also
found that RER regions often segregate with tumor sub-
type, with some RER regions being associated with
breast tumors of the luminal ER+ subtype, and others
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Fig. 7 The effect of estrogen on chromatin compaction and nuclear organization at subregion 2 of the 16p11.2 RER region. a Map of the 16p11.2
RER subregion 2 showing the location of ER binding sites (red) in MCF7 cells (from [38]). Below, the location of genes in the region is shown from
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gions we identified as in common between breast tu-
mors and breast cancer cell lines overlap with thoseidentified in bladder carcinoma [19]. However, five of
the RER regions identified in breast tumors, but not in
breast cancer cell lines, overlap those identified in
Rafique et al. Genome Biology  (2015) 16:145 Page 13 of 19bladder cancer (Table S4 in Additional file 1). This in-
cludes the domain at 3p22.3 that was found to be associ-
ated with increased histone methylation (H3K9me3 and
H3K27me3), histone hypoacetylation and a compact
chromatin structure in bladder cancer [16, 17].
Twelve RER regions identified here in breast tumors
overlap regions of LRES found in prostate cancer [3]
and two of these (at 8q22.3-q23.1 and 10q26.13) are also
in common with RER regions found in breast cancer cell
lines. One of the regions of LREA reported in prostate
cancer [18] overlaps the RER region at 12q21.31-q21.33
identified here. However, in breast cancers (ER−) this re-
gion seems to be down-regulated (i.e., subject to LRES)
compared with normal breast tissue (Fig. 2b).
These comparisons suggest that there are regions of
the human genome prone to recurrent RER in the con-
text of different epithelial cancers. This might be due to
the underlying mechanisms that give rise to RER being
particularly prone to dysregulation, and/or it could re-
flect selection for dysregulation of genes in these regions
during tumorigenesis.
RER regions do not seem to correspond to TADs
The median size of the RER regions that we identified in
breast cancer cells lines is similar (900 kb) to the average
size of TADs that have been defined in mammalian ge-
nomes from the ligation frequencies in Hi-C and 5C ex-
periments [42]. Indeed, it has been suggested that TAD
structure allows for coordinate gene regulation [7]. Hi-C
analysis is not available for the breast cancer cell lines
that we have analyzed by FISH here, but overall TAD
structure is remarkably similar between very diverse hu-
man cell types. Therefore, we analyzed the degree of
overlap between the RER regions defined here and TADs
identified in human embryonic stem cells (hESCs) and
IMR90 fibroblasts [43] as well as in the T47D breast
cancer cell line [44]. The latter cell line does not show
an RER phenotype at the 16p11.2 locus in our analysis
(Fig. 5c), but extensive coordinate gene regulation in re-
sponse to progesterone in these cells is reported to gen-
erally occur within TADs. However, even using a relaxed
threshold of 80 % overlap between a RER region and a
single TAD, we found that few of our RER regions cor-
respond to single TAD domains; six (23 %) for TADs in
hESCs, eight (31 %) for IMR90 and ten (38.5 %) for
T47D (Fig. 8a). Bootstrapping with randomly reposi-
tioned RER domains shows that this overlap is not sig-
nificantly different to that expected by chance.
Subregion 2 of the 16p11.2 RER region — the main
focus of study in this manuscript — spans a TAD
boundary in hESCs and IMR90 cells, but is contained
within one larger TAD from the T47D breast cancer cell
lines (Fig. 8b). We conclude that our breast cancer RER
regions do not correspond to TADs. However, wecannot exclude the possibility that this is because our
analyses of RER regions and TADs are based on data
from different cell lines or potentially because TADs are
disrupted in cancer.
An RER region at 16p11.2
One of the RER regions we identified as common to
both breast tumors and breast cancer cell line datasets
(16p11.2) encompasses the region previously reported as
regulated by LRES in estrogen-responsive breast cancer
cells [21] (Fig. 5). That study identified 11 domains of
LRES that were estrogen-mediated in breast cancer;
however, only the one at 16p11.2 is a significant RER
domain in our analyses of breast cancer cell lines and
tumors. The mechanism suggested to underpin this co-
ordinate gene repression was large-scale DNA looping.
However, in our analysis this 530 kb region (subregion 1
in Fig. 5) shows up-regulation of gene expression relative
to normal breast tissue (Fig. 2c).
Further examination of the 16p11.2 region, using
smaller window sizes for the transcription correlation
analysis (n < 10 genes), showed that the region of
epigenetic dysregulation could be resolved into two
separate blocks, which we designated as subregions 2
and 3 and which are located more centromere proximal
than subregion 1 (Fig. 5a). Subregion 3 contains a cluster
of KRAB-zinc finger genes, which are known to form a
large chromatin domain coated in the heterochromatin
protein CBX1 (HP1β) and in the H3K9 methyltransfer-
ase SUV39H1 [45]. Subregion 2 contains a number of
genes involved in cell proliferation and signaling
(TAOK2, PPP4C, MAPK2) as well as two genes (HIRIP3
and INO80E) involved in chromatin assembly and nu-
cleosome remodeling.
The ER and large-scale chromatin organization
Using 3C techniques, it has previously been suggested
that subregion 1 of the 16p11.2 RER region involves 14
gene promoters in a stable DNA loop structure that is a
physically repressive barrier to transcription in cancer
cells, including MCF7s [21]. However, using FISH we
found no significance difference in chromatin compac-
tion at this region, between ER+ MCF7 and ER− breast
cancer cell lines, that might be consistent with such a
chromatin structure (Fig. 5b). Cross-linked associations
captured by 3C methods have been reported that do not
necessarily correspond to spatial proximity as assayed by
FISH [46] and might even be indicative of cross-linking
not directly between the sequences concerned, but indir-
ectly through association to a common nuclear compart-
ment [47].
In contrast, we did find a significant visible difference
in long-range chromatin structure between ER+ (MCF7
and LY2) and ER− (MDAMB231 and MDAM468) breast
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(Fig. 5c). This altered chromatin structure was confined
to subregion 2 (Fig. 5b, d). Chromatin across this region
was less compact in MCF7 and LY2 cells than ER− cell
lines and a normal mammary epithelial cell line (Fig. 5a).
Moreover, this region was also less compact in an ER+
primary tumor tissue sample than in normal breast
tissue or an ER− tumor (Fig. 5c). A second ER+ cell line,
MDAMB361, showed a lesser, non-significant trend
towards de-compaction. This correlates with overexpres-
sion of ERBB2 due to copy-number amplification and
lower expression of subregion 2 genes in MDAMB361,
and with the lower expression of cluster 1 RER regions
like 16p11.2 in ERBB2 breast tumors. Therefore, it is
possible that ERBB2 expression leads to a lessening of
the estrogen-mediated de-compaction in subregion 2.
Crosstalk between ERBB2 and estrogen signaling has
long been observed in breast cancer and ERBB2 overex-
pression has been associated with estrogen-independentgrowth of ER+ breast cancer cell lines and resistance to
endocrine therapy in breast tumors [48–50].
Subregion 2 contains a high concentration of binding
sites for the ER (Fig. 6a) [38]. As well as altering histone
modifications and decondensing local chromatin struc-
ture [51], the ER has also been shown to visibly de-
compact large-scale chromatin architecture by recruiting
coactivators [37]. ER mainly binds at distal elements
away from target genes [52]; therefore, its ability to oper-
ate over a long range is key to its function. The work re-
ported here suggests that the reach of ER on chromatin
structure is further than previously thought, and results
in ligand-dependent chromatin unfolding. This is at
odds with the suggested formation of compact looped
chromatin structures as deduced from cross-linking
frequencies obtained by 3C-type methods [21], but is
consistent with the observed ability of ER to unfold
large-scale chromatin structures at transgene loci [37].
The unfolding of higher-order chromatin at a region of
Rafique et al. Genome Biology  (2015) 16:145 Page 15 of 19LREA, which we describe here, is redolent of the chro-
matin compaction at regions of LRES that we recently
reported in specific bladder cancer subtypes [16].
ER binding sites are concentrated in the distal 100 kb
of subregion 2 of the 16p11.2 RER region, yet transcrip-
tion correlation spreads over a larger (400 kb) domain.
As well as effects on chromatin folding, we also found
that estrogen affects the radial position of this chromo-
somal domain and this is consistent with recent evi-
dence linking chromatin unfolding to radial nuclear
organization [53]. Altered radial nuclear localization
brought about as a result of genomic rearrangement has
been suggested to result in long-range changes of gene
expression on the chromosome concerned [54]; thus, we
speculate that both altered chromatin folding and nu-
clear localization may contribute to the long-range epi-
genetic effects underlying the regional influence on gene
expression at the 16p11.2 RER region. We also note that
altered nuclear localization of specific genes has been re-
ported in breast cancer [55] and our study extends this
finding to larger genomic regions.
Conclusions
Copy-number independent coordinate dysregulation of
gene expression over large chromosome regions is found
in breast cancers and is specific to tumor subtype. For
one region of up-regulated gene expression in ER+ lu-
minal cancer this is linked to estrogen-dependent
unfolding of higher-order chromatin structure (chroma-
tin de-compaction) and a relocalization within the nu-
cleus in MCF7 cells.
Materials and methods
Ethics
Use of tumor material was approved by the Lothian Re-
search Ethics Committee (08/S1101/41), obtained under
the auspices of Experimental Cancer Medicine Centre
program (Edinburgh). Formalin-fixed paraffin-embedded
samples were obtained from a tissue bank and were fully
anonymized under the same approval.
Gene expression and CGH data sets
Oligonucleotide arrays (NCBI Gene Expression Omnibus
(GEO), platform GPL5345) and bacterial artificial chromo-
some (BAC) microarrays (GEO platform GPL4723) con-
sisting of 32,000 clones were used for global analysis of
gene expression and copy number in 359 breast tumors
[22]. All gene identifiers were mapped to Ensembl annota-
tions using Ensembl BioMart. Where multiple probes
were mapped to a gene the probe with the highest median
expression was used.
By examining copy number profiles for 145 primary
breast tumors using Scanning (2464 BACs at 1 Mb in-
tervals) and OncoBAC arrays (960 P1-derived artificialchromosome (PAC), or BAC clones), and gene expres-
sion profiles for 130 breast tumors (Affymetrix U133A
arrays), data were obtained for an additional dataset of
96 tumors [23].
Expression data for 42 invasive ductal carcinoma sam-
ples and 143 breast tissue samples with normal histo-
pathology were obtained from published Affymetrix
U133Plus 2.0 GeneChip data [28]. Raw data were proc-
essed using standardized Robust Multi-array Average
(RMA) normalization (Bioconductor Affy package) and
mapped to Ensembl gene annotations.
Expression profiles for 51 breast cancer cell lines were
obtained using Affymetrix U133A array and copy num-
ber data using Scanning and OncoBAC arrays [20].
Expression and copy number data for 48 common cell
lines were used for analysis. Raw data were processed
using RMA normalization (Bioconductor Affy package)
and mapped to Ensembl gene annotations.
CGH calling was done using the ‘R’ package CGHcall
[56]. Genome coordinates for CGH clones were mapped
to the UCSC Human Genome Browser (build 37/hg19)
and to their nearest ENSEMBL gene in the expression
data for the respective tumor or cell line. Copy number-
affected genes were then removed from the correspond-
ing expression dataset for that sample to produce a copy
number-independent gene expression file that was used
for all subsequent analyses.
Transcription correlation scores
The running score method, used previously to identify
regions of LRES in bladder cancer [19], was adopted
here. For each gene a TCS was calculated from the sum
of the Spearman rank correlation scores between the
RNA levels of a gene with that of each of its neighbors.
A sliding window approach (2n + 1 where n = number
of neighbors either side of gene) was used to calculate
scores for all genes. A Quantile-Quantile (Q-Q plot) in-
dicated a normal data distribution but with a tail of out-
liers at the high end that would be indicative of genes in
windows of coordinate regulation. Significance was
assessed using z scores and a significance threshold set
with p < 0.05 (for z scores unlikely to be observed in a
normal distribution characterized by the mean and
standard deviation of the TCSs observed).
RER regions were then delineated by extracting n number
of genes either side of the significant TCS genes (to get all
the genes in the sliding window). Regions containing less
than two significant TCS genes were discarded and
overlapping regions were merged together. Regions
were further refined by calculating the median gene ex-
pression value for each gene across all samples in the
dataset and working out the correlation between this
median and the value for the rest of the region. It was
then possible to assign p values (Spearman rank test)
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the region. Regions were thereby “trimmed” to the first
and last gene that had a p value <0.05.
To calculate the FDR, gene order was randomized for
the tumor dataset. A sliding window analysis of this ran-
domized data identified seven significant TCS genes in
three regions, which gives an FDR of 6.6 %.
The approach was validated against published bladder
carcinoma data [19] using a sliding window algorithm of
n = 7 (2n + 1 = 15 gene window). For the breast cancer
z score datasets, the number of genes with significant
scores (p < 0.05) was determined for 2n = 1 to 20 neigh-
boring genes. The number of significant genes plateaued
beyond n = 10. Therefore, a window size of n = 10 was
used for all analysis.
To determine the number of gene neighbors signifi-
cantly (p < 0.05) correlated with each gene with a signifi-
cant TCS, a p value was applied to the Spearman
correlation between each gene and its 20 nearest
neighbors.
To determine the number of genes correlated with the
genes with significant TCSs in the RER regions common
to breast tumors and cell lines, the mean z score expres-
sion for each RER region in tumors/cell lines was calcu-
lated (as for the RER clustering). Lists of all genes within
the RER windows were then used to ask how many of
those were present on each array and showed a signifi-
cant (p < 0.05) Spearman correlation with the mean RER
expression level. Genes with significant TCSs that were
in RER regions common to both breast tumors and to
cell lines were based on the lists of gene symbols given
in Table 1.
The mean expression level of each RER region in each
sample was defined by taking the mean z score of the
significant TCS genes it contains. Samples and RER re-
gions were then clustered using the Euclidian distance
and the Ward hierarchical clustering method.
Analysis of RER region overlap with TADs
HiC TAD domain locations for hESCs, IMR90 fibro-
blasts and the T47D breast cancer cell line were taken
from published data [43, 44]. BEDtools (v.2.17.0) was
used to determine how many of these domains over-
lapped with the 26 RER regions defined as common to
both breast tumors and cell lines [57]. To determine
whether the degree of overlap exceeded that expected by
chance, we randomly permutated the locations of the
RER regions 1000 times (excluding known genomic gaps
in the hg19 assembly) and re-assessed the degree of
overlap with TADs. RER regions and permutated regions
were defined as being contained within a TAD if ≥80 %
of the regions span was contained within a single TAD.
P values were defined as the percentage of times the ob-
served overlap was seen by chance.Cell culture
Luminal ER+ breast cancer cell lines (MCF7, LY2,
MDAMB361) and the basal ER-MDAMB231 were
grown in Dulbecco's Modified Eagle's medium (DMEM),
supplemented with 10 % FCS, 1 % P/S (100 units/ml
penicillin, 6.5 μg/ml streptomycin). The basal cell line
MDAM468 was grown in Leibovitz’s L15 medium
(Gibco) instead of DMEM. HMLE normal mammary lu-
minal epithelial cells were grown in Mammary Epithelial
Growth Media (Lonza).
For hormone deprivation, FCS was stripped of all en-
dogenous steroids. FCS (1 litre) was heat inactivated in a
waterbath at 56 °C for 30 minutes before addition of
2000U/l sulfatase. The serum was incubated for 2 hours
at 37 °C and then the pH adjusted to 4.2 using HCl. A
charcoal mix (for 1 litre: 5 g charcoal, 25 mg dextran
T70, 50 ml water) was then added and incubated over-
night at 4 °C with stirring. The following day the char-
coal was removed by centrifugation at 500 g for 30
minutes at 4 °C. The pH was then re-adjusted to 4.2 and
a second charcoal mix added, incubated overnight and
then removed. Centrifugation was repeated to remove
any residual charcoal and the pH adjusted to 7.2 with
NaOH. Stripped FCS was filter sterilized, aliquoted and
stored at −20 °C.
Semi-confluent cell cultures were transferred into
phenol-free DMEM (Gibco) supplemented with 5 %
L-glutamine, 5 % P/S, 10 % stripped FCS and incubated
for 72 hours (−E2). 17ß-estradiol (100 nM; Sigma) was
then added for 24 hours (+E2).Fluorescence in situ hybridization
DNA hybridization probes used for FISH were fosmid
probes obtained from BACPAC resources [58] and are
detailed in Table 2.
For 2D FISH, probes were labeled with either biotin-
16-dUTP or digoxigenin-11-dUTP (Roche) by nick
translation then hybridized as previously described [59]
but in the presence of human CotI to suppress
hybridization from repetitive sequences. Labeled DNA
(100–150 ng) and 12 μg of human Cot1 DNA were used
per slide.
For 3D FISH on tissue sections, parrafin-embedded
tissue sections were cut at 6 μm and laid on Superfrost+
slides. The slides were baked at 65 °C for 30 minutes to
melt the wax, washed four times in 200 ml xylene for 10
minutes, rehydrated through an ethanol series (four 10
minute washes in each of 100 %, 95 % and 70 % ethanol)
before being microwaved for a further 30 minutes in 0.1
M citrate buffer (pH 6). The slides were then allowed to
cool for 20 minutes in the citrate buffer solution before
being washed and stored in water. Slides were rinsed in
2× SCC before use.
Table 2 Fosmids probes used for FISH
Chromosomal region Whitehead probe name Other probe name Start (bp) End (bp) Midpoint (bp) Separation between probe
pair midpoints (kb)
16p11.2 RER
(sub region 1)
W12-1584N4 G248P86075G2 29,664,946 29,703,636 29,684,291 344
W12-1754H9 G248P8656D5 30,010,045 30,046,946 30,028,496
16p11.2 RER
(sub region 2)
W12-1754H9 G248P8656D5 30,010,045 30,046,946 30,028,496 373
W12-906G10 G248P8190D5 30,379,727 30,424,227 30,401,977
16p11.2 RER
(sub region 3)
W12-906G10 G248P8190D5 30,379,727 30,424,227 30,401,977 405
W12-497E18 G248P8178C9 30,788,769 30,824,965 30,806,867
16p11.2 RER
(sub region 4)
W12-497E18 G248P8178C9 30,788,769 30,824,965 30,806,867 380
W12-2222M4 G248P87014G2 31,166,763 31,207,277 31,187,020
16p11.2
(nonRER control)
W12-3081O2 G248P89434H1 28,483,429 28,519,288 28,501,359 418
W12-2889N9 G248P89117G5 28,899,528 28,938,582 28,919,055
11p15.4
(nonRER control)
W12-528M6 G248P8086G3 4,961,240 4,999,789 4,980,515 493
W12-2033J5 G248P85537E3 5,453,348 5,494,460 5,473,904
Probe names are from the Whitehead Fosmid database [58]. Alternative probe names can be used to view fosmids on the UCSC genome browser. All genome
locations (base pairs) are from the hg19 assembly of the human genome
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at 75 °C for 5 minutes then denatured for 3 minutes at
75 °C in 70 % formamide/2× SCC pH7.5. Slides were
then placed in ice cold 100 % ethanol for 3 minutes be-
fore further dehydration in 90 % and 100 % ethanol at
room temperature.
Digoxigenin-labeled probes were detected using sequen-
tial layers of fluorescein isothiocyanate (FITC)-conjugated
anti-digoxygenin and FITC-conjugated anti-sheep IgG.
Biotin-labeled probes were detected with sequential layers
of Texas Red-conjugated avidin, biotinylated anti-avidin
and Texas Red-conjugated avidin. Slides for 2D FISH
were mounted in Vectashield (Vector) with 0.5 μg/ml
DAPI. Slides for 3D FISH were incubated in 4× SSC/
1 % Tween with 50 ng/ml DAPI for 5 minutes before
mounting in Vectashield.
Image capture
Examination of nuclei after 2D FISH was carried out
using a Hamamatsu Orca AG CCD camera (Hamamatsu
Photonics (UK) Ltd, Welwyn Garden City, UK) fitted to
a Zeiss Axioplan II microscope with Plan-neofluar oil-
immersion objectives, a 100 W Hg source and Chroma
#8300 triple band pass filter set.
Examination of nuclei from tissue sections by 3D FISH
was carried out using a Hamamatsu Orca AG CCD
camera (Hamamatsu Photonics (UK) Ltd, Welwyn Gar-
den City, UK), Zeiss Axioplan II fluorescence micro-
scope with Plan-neofluar or Plan apochromat objectives,
a Lumen 200 W metal halide light source (Prior Scientific
Instruments, Cambridge, UK) and Chroma #89014ET
single excitation and emission filters (Chroma Technol-
ogy Corp., Rockingham, VT, USA) with the excitation
and emission filters installed in Prior motorized filterwheels. A piezoelectrically driven objective mount (PIFOC
model P-721, Physik Instrumente GmbH & Co, Karlsruhe)
was used to control movement in the z dimension.
Hardware control, image capture and analysis were per-
formed using Volocity (Perkinelmer Inc, Waltham,
MA, USA). Images were captured at 200 nm intervals
in the z axis and were deconvolved using a calculated
point spread function (PSF) with the constrained itera-
tive algorithm of Volocity.Image analysis
Image capture and analysis of nuclear size, radial nuclear
position and distance between the hybridization signals
after 2D FISH were performed with scripts written for
IPLab Spectrum (Scanalytics Copr, Fairfax, VA, USA).
Scripts for analysis of 3D FISH images were carried out
using scripts written for Velocity.
For 2D FISH data analysis, the mean-square inter-
probe distances (d2) were normalized to nuclear area
(r2) as previously described [32]. The difference between
the distribution of squared inter-probe distances
between datasets was assessed statistically using the
Wilcox test with a cutoff of p < 0.05. Radial nuclear pos-
ition was assessed from the proportion of hybridization
signals across five concentric shells of equal area eroded
from the periphery (shell 1) to the center (shell 5) of the
nucleus as previously described [41, 53].Data availability
The following data used in this study were extracted
from publically available sources. Oligonucleotide arrays
(NCBI GEO, platform GPL5345) and BAC microarrays
(GEO platform GPL4723) were used for global analysis
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described in [22]. Copy number data for an additional
tumor set in [23] were obtained from the Lawerence
Berkley Breast Cancer lab. Gene expression profiles for
these tumors are available from ArrayExpress, accession
number E-TABM-158. Expression data for invasive ductal
carcinoma samples and 143 breast tissue samples with
normal histopathology from [28] are available from NCBI
GEO under accession number GSE10780. Expression
data for normal breast in [29] are under accession num-
bers GSE5460 and GSE7904. Expression profiles for 51
breast cancer cell lines described in [20] were obtained
using Affymetrix U133A array from ArrayExpress acces-
sion number E-TABM-157. ChIP-seq data for ER from
[38] are available under ArrayExpress number E-
MTAB-223.
Additional file
Additional file 1: Supplementary Tables S1–S4 and supplementary
Figures S1–S5. (PDF 2375 kb)
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